LLY compared with AVIR: revenue, margins and what each company keeps, and the suppliers and customers both name

LLYELI Lilly & Co

Mkt capRevenueRevenue

AVIRAtea Pharmaceuticals, Inc.

Mkt capRevenueRevenue

Compare

LLYELI Lilly & Co

AVIRAtea Pharmaceuticals, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

LLY

3 of 4at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±5.1%▲+6.63%×1.29

Q2 FY26±6.2%▲+4.86%×0.79

Q1 FY26±5.3%▲+9.80%×1.85

Feb 4 '26±6.1%▲+10.33%×1.69

AVIR

1 of 4at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±11.0%▲+0.20%×0.02

May 13 '26±12.9%▼−16.91%×1.31

= impliedLLY realized, solidAVIR realized, hatchedOne scale, both sides: full bar = 25%× = |realized| ÷ impliedSource: market data

Q1 FY26

±18.1%

▲+11.13%

×0.61

Jan 8 '26±24.5%▲+3.74%×0.15

LLYELI Lilly & Co

1,360.90▼−0.28%· post 1,358.90

Mkt cap$1.2TRevenue$24.4BQ3 FY26Revenue$65.2BFY25

AVIRAtea Pharmaceuticals, Inc.

4.30▲+1.90%· post 4.30

ClosedNov 6 '26

Mkt cap$345.7MRevenue—Revenue—

Compare

ClosedNov 6 '26

LLYELI Lilly & Co

AVIRAtea Pharmaceuticals, Inc.

1,360.90▼−0.28%post 1,358.90

Price

4.30▲+1.90%post 4.30

$1.2T

Mkt cap

$345.7M

Q3 FY26$24.4B

Revenue

—

FY25$65.2B

Revenue

—

LLY1,360.90▼−0.28%vsAVIR4.30▲+1.90%ClosedNov 6 '26